Wallace J D, Cuneo R C, Bidlingmaier M, Lundberg P A, Carlsson L, Boguszewski C L, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosén T, Strasburger C J
Metabolic Research Unit, Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane 4102, Australia.
J Clin Endocrinol Metab. 2001 Apr;86(4):1731-7. doi: 10.1210/jcem.86.4.7379.
GH is being used by elite athletes to enhance sporting performance. To examine the hypothesis that exogenous 22-kDa recombinant human GH (rhGH) administration could be detected through suppression of non-22-kDa isoforms of GH, we studied seventeen aerobically trained males (age, 26.9 +/- 1.5 yr) randomized to rhGH or placebo treatment (0.15 IU/kg/day for 1 week). Subjects were studied at rest and in response to exercise (cycle-ergometry at 65% of maximal work capacity for 20 min). Serum was assayed for total GH (Pharmacia IRMA and pituitary GH), 22-kDa GH (2 different 2-site monoclonal immunoassays), non-22-kDa GH (22-kDa GH-exclusion assay), 20-kDa GH, and immunofunctional GH. In the study, 3 h after the last dose of rhGH, total and 22-kDa GH concentrations were elevated, reflecting exogenous 22-kDa GH. Non-22-kDa and 20-kDa GH levels were suppressed. Regression of non-22-kDa or 20-kDa GH against total or 22-kDa GH produced clear separation of treatment groups. In identical exercise studies repeated between 24 and 96 h after cessation of treatment, the magnitude of the responses of all GH isoforms was suppressed (P < 0.01), but the relative proportions were similar to those before treatment. We conclude: 1) supraphysiological doses of rhGH in trained adult males suppressed exercise-stimulated endogenous circulating isoforms of GH for up to 4 days; 2) the clearest separation of treatment groups required the simultaneous presence of high exogenous 22-kDa GH and suppressed 20-kDa or non-22-kDa GH concentrations; and 3) these methods may prove useful in detecting rhGH abuse in athletes.
生长激素（GH）正被一些优秀运动员用于提高运动成绩。为了验证通过抑制GH的非22 kDa异构体能够检测出给予外源性22 kDa重组人生长激素（rhGH）这一假设，我们研究了17名经过有氧训练的男性（年龄26.9±1.5岁），他们被随机分为rhGH治疗组或安慰剂治疗组（0.15 IU/kg/天，持续1周）。对受试者在静息状态下以及运动后（以最大工作能力的65%进行20分钟的自行车测力计运动）进行研究。检测血清中的总GH（Pharmacia免疫放射分析和垂体GH）、22 kDa GH（两种不同的双位点单克隆免疫分析）、非22 kDa GH（22 kDa GH排除分析）、20 kDa GH和免疫功能GH。在研究中，末次给予rhGH后3小时，总GH和22 kDa GH浓度升高，反映了外源性22 kDa GH。非22 kDa和20 kDa GH水平受到抑制。非22 kDa或20 kDa GH相对于总GH或22 kDa GH的回归分析使治疗组之间有明显区分。在停止治疗后24至96小时重复进行的相同运动研究中，所有GH异构体的反应幅度均受到抑制（P<0.01），但相对比例与治疗前相似。我们得出以下结论：1）在经过训练的成年男性中，超生理剂量的rhGH可抑制运动刺激的内源性循环GH异构体长达4天；2）治疗组之间最明显的区分需要同时存在高浓度的外源性22 kDa GH以及受抑制的20 kDa或非22 kDa GH浓度；3）这些方法可能在检测运动员滥用rhGH方面有用。
